听着都别扭,这原本就是一个不该出现的词汇,但这个沉重的词汇,的确是由这些年有些不负责任企业所催生出的。就在上一年,频频曝光的“齐二药事件”、“安徽阜阳特大制造贩卖假药案”等药品安全事件,不断触动公众脆弱的神经,同时也影响着医药行业的健康发展。在诸多的拷问中,虽说被严肃查处的原国家药监局局长郑筱萸一案,折射了药品行政审批和监管上的漏洞和缺陷, Listen to all uncomfortable, this was originally a word that should not appear, but this heavy word, indeed by some of these irresponsible businesses were born. In the previous year, the frequently exposed “Qi two drug incident”, “Anhui Fuyang large manufacturing and selling fake drugs” and other drug safety incidents continue to touch the public vulnerable nerves, but also affect the health of the pharmaceutical industry development of. In many interrogations, although the case of Zheng Xiaoyu, former director of the State Food and Drug Administration, which was severely punished, reflects the loopholes and defects in administrative examination, approval and supervision of pharmaceutical products,